2023-04-26-深交所-兰卫医学_2023年一季度报告_11页_785kb

报告摘要

Summary of Shanghai Lanwell Medical Testing Co., Ltd. 2023 Q1 Financial Report

Revenue and Profit Decline: The company reported a significant drop in revenue for the first quarter of 2023, down 50.15% to 412.6 million yuan, compared to 827.7 million yuan in the same period last year. Net profit also fell sharply by 87.92% to 21.4 million yuan, affected by reduced sales volume and higher operating costs. Other financial metrics, such as basic earnings per share (0.0535 yuan vs 0.4425 yuan), declined.
Financial Highlights: In January-March 2023, the company's assets decreased 7.59% to 3.46 billion yuan, while liabilities rose slightly. Non-recurring items, including government subsidies and investment gains, contributed to fluctuations in earnings, with a non-recurring profit gain of about 10.4 million yuan. The report was unaudited.
Key Changes: Reasons for declines include reduced revenue due to lower medical testing demand and increased interest expenses from bank borrowings (+895%). Conversely, assets like in-progress construction increased due to new lab developments, and other operating cash flows improved due to government support funds.
Shareholder Information: Total shareholders numbered 35,725 at quarter-end. The top shareholders included Shanghai Lanwell Investment Co. (37.34% stake) and individuals like Mr. Zeng Weixiong (13.42%). No major voting rights changes or financing activities were reported.
Other Matters: The company announced the award of 2022 restricted stock units to employees, as detailed in separate announcements.